Member Info for B2HS2L

From 23.04.2021 RNS:
"* Development of test to detect a variant originally identified in India, launch expected week commencing 26 April 2021. 8th Assay to the portfolio."

I haven't heard any more about the release of this test since this RNS.
Anyone else heard please.

For the record here is info on genomic surveillance assays from other manufacturers, with dates they were first announced.

None have FDA authorisations to date, so are Research Use Only by default.
+++
https://perkinelmer-appliedgenomics.com/home/sars-cov-2-testing-solutions/sars-cov-2-variants/

NGS = Next Generation Sequencing

https://perkinelmer-appliedgenomics.com/home/sars-cov-2-testing-solutions/nextflex-variant-seq-sars-cov-2-kit/

Note 7 hour process duration.

+++

26.03.21 -
Roche launches test to monitor emerging coronavirus variants

https://pharmaphorum.com/news/roche-launches-test-to-monitor-emerging-coronavirus-variants/

Roche has launched a new test that will help monitor emerging variants of the SARS-CoV-2 coronavirus.

In a statement the company said the cobas SARS-CoV-2 Variant Set 1 Test is designed to detect key spike mutations in virus variants associated with increased human-to-human transmission.

+++

10.03.2021 -

https://thermofisher.mediaroom.com/2021-03-10-Thermo-Fisher-Scientific-Launches-Customizable-TaqMan-SARS-CoV-2-Mutation-Panel

Thermo-Fisher launches Customizable TaqMan SARS-CoV-2 Mutation Panel.
These are the details, - Variants and sub-variants, but not the Bristol or California variants:

https://www.thermofisher.com/uk/en/home/clinical/clinical-genomics/pathogen-detection-solutions/real-time-pcr-research-solutions-sars-cov-2/mutation-panel.html?cid=fl-mutationpanel#orderinginfo

Bruce, - I thought the success of hospital trials lead to home trials.
It wasn't the other way round.

Well one possibility is that IT-IS has bought a licence, and that is what the vacancies are all about! - Laughing out loud :-)

Why has there been so little news on usage of this device since launch in Mid-March 2021?

SYN00GOLD -
"Treating people at home/ sending patients home from hospital earlier will be most beneficial to health providers globally."

If the hospitals and clinics are swamped with too many people with Covid symptoms, the only choice is to treat them at home. In different countries, what that might cost and who pays is another matter.

Private patients might prefer a treatment at home if they can afford the treatment.

Reference the discussions on Tuesday concerning this Attogene link:
https://www.globenewswire.com/news-release/2021/05/11/2226791/0/en/Attogene-to-expand-SARS-CoV-2-variants-testing-in-the-United-States.html

"Specifically, Attogene will add to its current portfolio of PrimerDesign reagents (Novacyt Group), eight new RUO assays, which arguably may be the most complete variant detection portfolio currently available worldwide to address the globally prevalent variants of SARS-CoV-2. The company is striving to meet all arising COVID-19 challenges as quickly as possible and will also make available an assay to detect the novel variants originally identified in India."

++++
I emailed Attogene and asked
"Your website offers the Primerdesign SNPsig® VariPLEX™ (Covid-19) Real-Time PCR Assay under the Research Use Only part number, - R00137.
Could you provide an estimate when you will be offering the assay licensed for diagnostic procedures in US please?
I'm aware of the CE-IVD approved product part number D00060."

Response :
"We are unable to comment on FDA applications.
However, this kit is being used in a similar fashion as other kits in clinical settings for detecting variants from diagnosed samples.
There are no tests approved by the FDA for diagnosing variants to my knowledge."

+++
Sales should be 'Robust' then.

When are booster jabs scheduled to be available please.
I haven't seen any dates, but my research has not included booster availability.

neilrich -
Answer on this link:
https://mobile.twitter.com/Larry64450205/status/1387487053684879363

https://twitter.com/JackTaylorJTP/status/1390299075824791552

This Jack Taylor tweet confirms that IT-IS have moved into premises in Great Broughton a few miles away from original premises in Stokesley.

(Item for the spreadsheet Shaun?)

We don't know if it is additional to or instead of the old premises, but lets hope they now have no problems keeping up with demand.

The more I think about it, the more I think presenting exciting long-term plans for Novacyt during Q2 this year is not fully possible without the M&A activity occurring first.
Perhaps the DHSC debacle will be sorted out in a similar timescale, and if in our favour, speculation concerning catapulting share prices will have arrived.
That really would be the time for a GM interview if talk about improving PR is not hot air.

Ad4you - re your 10:09 -
GM quote "In addition, we look forward to presenting exciting long-term plans for Novacyt during Q2 this year as we continue to define our strategy for delivering sustainable, long-term growth."

Thinking about this news event, wouldn't it be putting the cart in front of the horse if these long-term plans were revealed before any M&A activity?

GM previously mentioned M&A activity around H1 2021.
The two timescales seem to fit, and we might expect both at the same time.
++++

Wasn't it Fergie who had special attention paid to her toes?
- You seem in good company kaeren.

Macmdude - Looked at your history.
You know about emotional attachment to a share is, but your not sure what a deramper is?
Times up, - your still a fraud.
Filtered.

kaeren, - this looked helpful:
https://patient.info/foot-care/broken-toe
Take particular care of yourself, and get well soon.

New to Deramping ?
New to share ownership?
New to NCYT share ownership?
Well I guess I am emotionally attached to some extent after 15 months of NCYT ownership.
But I'm still here, - sold very little, and expecting great things soon.
Are you with me and many others here, or are you just another deramper?

Macmdude - posts=6 = recycled deramper.
That's the only conclusion looking at your past posts.

You've all heard the term 'follow the money'.
Is GM planning to sell the company, - no.
He would not have so many vacancies if this were the case.
He is investing in more staff to bring the dream of mid-cap status closer.
So I'm 'following the money' here.
Awaiting M&A activity due soon, or Anthony Dyer is wasting his / our time.

Remember this from a 02.06.2020 RNS VanV?
"Novacyt is also pleased with the progress it is making in the US market and expects to update the market in due course."

That update never happened.

So I'm taking GM's expected update statement with a pinch of salt at the present moment.

From 15.10.2020 IT-IS Acquisition RNS:
"In addition, an earn out of up to £1.9 million in cash is payable to the directors of IT-IS over the next two years, subject to certain manufacturing targets being achieved."

I have always thought 2 years was a very long time for an earn out, when Chartwell were available to improve the 'here and now' production situation.
NCYT bought everything, including the rights to any R&D / new products.
IMO GM negotiated the 2 year earn out with directors because he had a few jobs for them up his sleeve.
We will soon see the first product I believe.

Hi Shaun,

My view is

1 The Toyota manufacturing site has been chosen for manufacture of Antigen LFT's.
2 The *contract award notice* details -
Concepts:
plant engineering design
supply of product
uk lateral flow team
supply of product and manufacturing engineers for uk lateral flow team
manufacturing engineers
upscale project accelerator team lft

3 Sounds like Toyota are contracted to supply facility / engineers / whatever it takes to produce Antigen LFT's.

But who's Antigen LFT's? :)